At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 12, 2026 at 17:16 ET
CytoSorbents reported Q3 2026 revenue of $9.7M (+3% YoY), slightly below the $9.9M consensus, and a GAAP net loss of $0.58 per share, which was narrower than the $-0.90 consensus estimate. The company achieved operating cash flow breakeven (excluding restructuring payments), a key milestone, but revenue growth remains modest and the German market declined 20% YoY.
- Revenue $9.7M, +3% YoY vs $9.5M (consensus $9.9M)
- GAAP net loss $0.58 per share vs consensus $-0.90 (narrower loss)
- Operating cash flow positive $43K (excluding $251K restructuring payments), achieving breakeven target
- Gross margin improved to 75% from 70% a year ago
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access